BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 26189107)

  • 21. AEE788 is a vascular endothelial growth factor receptor tyrosine kinase inhibitor with antiproliferative and proapoptotic effects in acute myeloid leukemia.
    Barbarroja N; Torres LA; Rodriguez-Ariza A; Valverde-Estepa A; Lopez-Sanchez LM; Ruiz-Limon P; Perez-Sanchez C; Carretero RM; Velasco F; López-Pedrera C
    Exp Hematol; 2010 Aug; 38(8):641-52. PubMed ID: 20380868
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting FGFR/PDGFR/VEGFR impairs tumor growth, angiogenesis, and metastasis by effects on tumor cells, endothelial cells, and pericytes in pancreatic cancer.
    Taeger J; Moser C; Hellerbrand C; Mycielska ME; Glockzin G; Schlitt HJ; Geissler EK; Stoeltzing O; Lang SA
    Mol Cancer Ther; 2011 Nov; 10(11):2157-67. PubMed ID: 21885862
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death.
    Heo SK; Noh EK; Yu HM; Kim DK; Seo HJ; Lee YJ; Cheon J; Koh SJ; Min YJ; Choi Y; Jo JC
    BMC Cancer; 2020 Dec; 20(1):1193. PubMed ID: 33276759
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Emodin and Its Combination with Cytarabine Induce Apoptosis in Resistant Acute Myeloid Leukemia Cells in Vitro and in Vivo.
    Chen Y; Gan D; Huang Q; Luo X; Lin D; Hu J
    Cell Physiol Biochem; 2018; 48(5):2061-2073. PubMed ID: 30099447
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Abivertinib synergistically strengthens the anti-leukemia activity of venetoclax in acute myeloid leukemia in a BTK-dependent manner.
    Huang S; Li C; Zhang X; Pan J; Li F; Lv Y; Huang J; Ling Q; Ye W; Mao S; Huang X; Jin J
    Mol Oncol; 2020 Oct; 14(10):2560-2573. PubMed ID: 32519423
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TGF-β-Neutralizing Antibody 1D11 Enhances Cytarabine-Induced Apoptosis in AML Cells in the Bone Marrow Microenvironment.
    Tabe Y; Shi YX; Zeng Z; Jin L; Shikami M; Hatanaka Y; Miida T; Hsu FJ; Andreeff M; Konopleva M
    PLoS One; 2013; 8(6):e62785. PubMed ID: 23826077
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of a Multitargeted Tyrosine Kinase Inhibitor for the Treatment of Gastrointestinal Stromal Tumors and Acute Myeloid Leukemia.
    Lin WH; Wu SY; Yeh TK; Chen CT; Song JS; Shiao HY; Kuo CC; Hsu T; Lu CT; Wang PC; Wu TS; Peng YH; Lin HY; Chen CP; Weng YL; Kung FC; Wu MH; Su YC; Huang KW; Chou LH; Hsueh CC; Yen KJ; Kuo PC; Huang CL; Chen LT; Shih C; Tsai HJ; Jiaang WT
    J Med Chem; 2019 Dec; 62(24):11135-11150. PubMed ID: 31721578
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Src and c-Kit kinase inhibitor dasatinib enhances p53-mediated targeting of human acute myeloid leukemia stem cells by chemotherapeutic agents.
    Dos Santos C; McDonald T; Ho YW; Liu H; Lin A; Forman SJ; Kuo YH; Bhatia R
    Blood; 2013 Sep; 122(11):1900-13. PubMed ID: 23896410
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Disruption of gap junctions attenuates acute myeloid leukemia chemoresistance induced by bone marrow mesenchymal stromal cells.
    Kouzi F; Zibara K; Bourgeais J; Picou F; Gallay N; Brossaud J; Dakik H; Roux B; Hamard S; Le Nail LR; Hleihel R; Foucault A; Ravalet N; Rouleux-Bonnin F; Gouilleux F; Mazurier F; Bene MC; Akl H; Gyan E; Domenech J; El-Sabban M; Herault O
    Oncogene; 2020 Feb; 39(6):1198-1212. PubMed ID: 31649334
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long noncoding RNA, CCDC26, controls myeloid leukemia cell growth through regulation of KIT expression.
    Hirano T; Yoshikawa R; Harada H; Harada Y; Ishida A; Yamazaki T
    Mol Cancer; 2015 Apr; 14():90. PubMed ID: 25928165
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Valproic acid enhances the antileukemic effect of cytarabine by triggering cell apoptosis.
    Liu N; Wang C; Wang L; Gao L; Cheng H; Tang G; Hu X; Wang J
    Int J Mol Med; 2016 Jun; 37(6):1686-96. PubMed ID: 27082972
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Deoxycytidine kinase is downregulated under hypoxic conditions and confers resistance against cytarabine in acute myeloid leukaemia.
    Degwert N; Latuske E; Vohwinkel G; Stamm H; Klokow M; Bokemeyer C; Fiedler W; Wellbrock J
    Eur J Haematol; 2016 Sep; 97(3):239-44. PubMed ID: 26613208
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interleukin-8 blockade prevents activated endothelial cell mediated proliferation and chemoresistance of acute myeloid leukemia.
    Vijay V; Miller R; Vue GS; Pezeshkian MB; Maywood M; Ast AM; Drusbosky LM; Pompeu Y; Salgado AD; Lipten SD; Geddes T; Blenc AM; Ge Y; Ostrov DA; Cogle CR; Madlambayan GJ
    Leuk Res; 2019 Sep; 84():106180. PubMed ID: 31299413
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Additive effect of PTK787/ZK 222584, a potent inhibitor of VEGFR phosphorylation, with Idarubicin in the treatment of acute myeloid leukemia.
    Barbarroja N; Torres LA; Luque MJ; Carretero RM; Valverde-Estepa A; Lopez-Sanchez LM; Rodriguez-Ariza A; Velasco F; Torres A; López-Pedrera C
    Exp Hematol; 2009 Jun; 37(6):679-91. PubMed ID: 19463770
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MicroRNA-143 sensitizes acute myeloid leukemia cells to cytarabine via targeting ATG7- and ATG2B-dependent autophagy.
    Zhang H; Kang J; Liu L; Chen L; Ren S; Tao Y
    Aging (Albany NY); 2020 Oct; 12(20):20111-20126. PubMed ID: 33077697
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of ubiquitin-specific protease 7 sensitizes acute myeloid leukemia to chemotherapy.
    Cartel M; Mouchel PL; Gotanègre M; David L; Bertoli S; Mansat-De Mas V; Besson A; Sarry JE; Manenti S; Didier C
    Leukemia; 2021 Feb; 35(2):417-432. PubMed ID: 32447346
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pairing MCL-1 inhibition with venetoclax improves therapeutic efficiency of BH3-mimetics in AML.
    Hormi M; Birsen R; Belhadj M; Huynh T; Cantero Aguilar L; Grignano E; Haddaoui L; Guillonneau F; Mayeux P; Hunault M; Tamburini J; Kosmider O; Fontenay M; Bouscary D; Chapuis N
    Eur J Haematol; 2020 Nov; 105(5):588-596. PubMed ID: 32659848
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cyclooxygenase inhibitors potentiate receptor tyrosine kinase therapies in bladder cancer cells in vitro.
    Bourn J; Cekanova M
    Drug Des Devel Ther; 2018; 12():1727-1742. PubMed ID: 29942116
    [TBL] [Abstract][Full Text] [Related]  

  • 39. LT-171-861, a novel FLT3 inhibitor, shows excellent preclinical efficacy for the treatment of FLT3 mutant acute myeloid leukemia.
    Yu Z; Du J; Hui H; Kan S; Huo T; Zhao K; Wu T; Guo Q; Lu N
    Theranostics; 2021; 11(1):93-106. PubMed ID: 33391463
    [No Abstract]   [Full Text] [Related]  

  • 40. MTH1 Inhibitor TH1579 Induces Oxidative DNA Damage and Mitotic Arrest in Acute Myeloid Leukemia.
    Sanjiv K; Calderón-Montaño JM; Pham TM; Erkers T; Tsuber V; Almlöf I; Höglund A; Heshmati Y; Seashore-Ludlow B; Nagesh Danda A; Gad H; Wiita E; Göktürk C; Rasti A; Friedrich S; Centio A; Estruch M; Våtsveen TK; Struyf N; Visnes T; Scobie M; Koolmeister T; Henriksson M; Wallner O; Sandvall T; Lehmann S; Theilgaard-Mönch K; Garnett MJ; Östling P; Walfridsson J; Helleday T; Warpman Berglund U
    Cancer Res; 2021 Nov; 81(22):5733-5744. PubMed ID: 34593524
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.